Date: 2012-10-23
Type of information: Services contract
Compound: generation of induced pluripotent stem (iPS) cell lines of research grade and differentiation of iPS cells toward specific tissue cell type for research use
Company: Cellectis (France) NIH (USA)
Therapeutic area:
Type agreement: services
Action mechanism:
Disease:
Details: Cellectis bioresearch, the specialist in genome customization and commercial subsidiary of Cellectis been awarded a second contract to provide services to the National Institutes of Health (NIH) and certain other government agencies. Under the terms of the contract, the scope of work includes generation of induced pluripotent stem (iPS) cell lines of research grade and differentiation of iPS cells toward specific tissue cell type for research use.
This second major contract is following the one announced October 16th (See http://biopharmanalyses.fr/agreements/?pageid=967).
Financial terms:
Latest news:
